Evidence map›Paper›PMID 41746574›Full record

ArticleAnnals of surgical oncology2026

Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.

Eyal Mor, Sameer Apte, Mathias Bressel, Kristy K Broman, Tina J Hieken, Roger Olofsson Bagge, Russell S Berman, Ann Y Lee, Anke M Kuijpers, David W Ollila and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eyal MorPeter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. eyal_more@hotmail.com.ORCID http://orcid.org/0000-0002-3235-2946
Sameer AptePeter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Mathias BresselPeter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Kristy K BromanUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Tina J HiekenDepartment of Surgery, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.
Roger Olofsson BaggeDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Russell S BermanDepartment of Surgery, Weill Cornell Medicine, New York, NY, USA.
Ann Y LeeDepartment of Surgery NYU Langone Health, New York, NY, USA.
Anke M KuijpersDivision of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
David W OllilaDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
Alexander C J van AkkooiMelanoma Institute Australia, Sydney, NSW, Australia.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
David E GyorkiPeter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSentinel lymph node biopsy (SLNB) is recommended as a staging tool for some patients with primary melanoma to select for adjuvant therapy. This study investigates the impact of adjuvant immunotherapy on recurrence patterns in patients managed with nodal surveillance (NS). PATIENTS AND

methodsA multicenter, retrospective analysis was performed, including patients with SLN-positive melanoma who were followed with NS. Outcomes were 5-year recurrence-free survival (RFS) and overall survival (OS). Factors associated with recurrence were evaluated using Cox proportional hazards models.

resultsA total of 544 patients were treated at 10 centers across Australia, Europe, and the USA from 2017 to 2023. Adjuvant immunotherapy was given in 235 (43%) patients. Patients who received adjuvant immunotherapy had melanomas at higher risk of recurrence (higher Breslow thickness p < 0.001, higher rates of ulceration p = 0.003, and higher SLN tumor burden p < 0.001). Among patients receiving adjuvant immunotherapy, the 5-year cumulative incidence of nodal, in-transit, and distant recurrence were 25% (95% CI 18-32%), 6% (95% CI 3-9%) and 19% (95% CI 14-26%), respectively. In the multivariable analysis, factors associated with recurrence included older age, higher stage, cervical nodal basin and larger nodal burden, while adjuvant therapy was associated with a lower risk of recurrence (HR 0.7, 95% CI 0.5-0.9).

conclusionsAdjuvant immunotherapy was given in higher risk patients and reduced the risk of recurrence. Given the significant mismatch in patient populations between treated and untreated groups, it was not possible to assess for a treatment-related effect on pattern of recurrence. There is, however, a clear stage-related difference in recurrence pattern among patients with sentinel node positive disease.

Indexed as

ImmunotherapyMelanomaNeoplasm Recurrence, LocalSentinel Lymph NodeSentinel Lymph Node BiopsySkin NeoplasmsAdultAgedCutaneous Malignant MelanomaFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedPrognosis

Identifiers

PMID41746574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.